RTP Mobile Logo
The Current Application of and New Directions in Cancer Immunotherapy
Released April 2015

Featuring interviews with Drs David F McDermott and Julie R Brahmer. Special feature: Bonus web-only audio. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. The future of immunotherapy may be more promising than ever imagined, as a number of novel approaches are already delivering unprecedented outcomes. However, with the many exciting advances that are rapidly occurring, a number of vexing questions and clinical challenges are emerging simultaneously. Featuring information on the latest research developments along with expert perspectives from clinical investigators, this CME program is designed to assist medical oncologists, hematology-oncology fellows and other allied cancer professionals to better understand the implications of emerging data and optimally incorporate existing and novel immunotherapeutic strategies into the care of patients with various cancers.

    LEARNING OBJECTIVES

    • Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various tumor types evade this process to proliferate and grow.
    • Compare and contrast the mechanisms of action, efficacy and safety/toxicities of approved and investigational immunotherapies for the treatment of melanoma, non-small cell lung cancer, renal cell carcinoma and other solid tumors and hematologic cancers to determine the current and/or potential utility of each in clinical practice.
    • Appreciate the recent FDA approvals of the anti-PD-1 antibodies pembrolizumab and nivolumab, and discern how these agents can be appropriately integrated into clinical practice for patients with metastatic melanoma.
    • Counsel patients about and define supportive management strategies for immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics.
    • Recall the scientific rationale for ongoing investigations of novel immunotherapeutic approaches, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue



    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue



    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should listen to the MP3s and bonus web-only audio.

    CME credit is no longer available for this issue



    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr McDermottAdvisory Committee: Pfizer Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Roche Laboratories Inc; Contracted Research: Novartis Pharmaceuticals Corporation. Dr BrahmerAdvisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Paid Research: AstraZeneca Pharmaceuticals LP; Uncompensated Research: Bristol-Myers Squibb Company.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology and Prometheus Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2015
    Expiration date: April 2016

Acknowledge and close

Listen to audio:
The Current Application of and New Directions in Cancer Immunotherapy
Released April 2015

Featuring interviews with Drs David F McDermott and Julie R Brahmer. Special feature: Bonus web-only audio. (Audio Content)

Read print: